Genus Lifesciences is a national leader in the submission of 505(b)(2) New Drug Applications, for products previously sold as Unapproved Products.


Diversion and Abuse Resistant Technologies (DART) allows dosage manufacturers to improve a product’s resistance to abuse, illegal diversion, and potential overdose.


Genus Lifesciences™ has a rigorous R&D program. With global reach, Genus Lifesciences’™ R&D plan benefits from the vast intellectual resources and partnerships with foreign and domestic companies.